Member Info for LovableLumax

I feel for you wassap, you noted a little while ago how few shares the BOD had between them. Always a bad sign when they have little skin in the game. You should have followed your gut. Main thing is to learn from this. I mean even uber ramper 2Phevs sold out, think he was dumping between 0.7 and 0.5p so looking at what he'd get now he has done well (relatively speaking). I hope you haven't lost too much and best of luck.

Bullish, PWC would had had their trainees working on this and have walked away, the do so as a last resort. They are burning cash and the market knows this so the cash in bank being discounted. The market also knows a raise will be needed for new auditor to sign off accounts on a going concern basis. Check out the new auditors website, says it all.

Triplelift walked away for good reason. They were a partner as per the 8 April RNS and by end of June they have walked away as didn;t want to commit resource. If they believed this had legs would they walk away? Will large media cos be signing up with Mirriad? Where was the chairman at the interim report, his chance to reassure the market? Why are IIs selling and not buying all the way down here? When will programmatic be ready? Why did demand fall massively in H1? Where are all the strategic partners? Where are the material RNSs?

lotm has me on ignore and encouraged others to. i am not happy he'll lose money and i applauded 2phevs who sold out at a large loss (double the current price or so) but i applauded his decision all the while lotm continues to post nonsense linkedin posts. the reason there are no rnss is because they are not winning material business. these lifestyle plcs rely on mug punters ramping to keep the gravy train going. the only reason the chairman hasn't resigned is the money he put in on the raise he wants to take salary as long as possible to get cash back. can't blame him. i feel sorry for investors who bought due to lotm and his ramping but i don't feel for him once bit as he continued to ramp this dog **** on other boards. a lesson is read and understand rnss, cash burn and ignore rampy investors in over their heads who ignore posters with balance and want other posters to just listen to ramps.

Sorry I meant mirriad will have used newly qualified accountants on such a small account and used as a training exercise. The fact they didn't even want to keep as a training exercise sets off alarm bells. Another AiM lifestyle business that's shafted investors but the CEO want to keep the show going as long as pos to get his £40k a month and pay his loyal senior stafff for as long as pos. No wonder they're laying more staff off, keep the gravy train going for as many months as pos. An auditor trying to show integrity. Well I never.

Auditor’s resign as a last resort. Mirriad would have had juniors working on the account for training but I guess PWC don’t want to be linked with these charlatans.

No doubt LOTM will say the fact they are saying the new auditor will need to be reapprove suggests they will be able to get a raise away to sign the accounts off and have an AGM to reappoint them. I suggest that won’t be the case. LOTM can lower his average though.

I thought 4 years ago this would take off. I’ve seen the CEO milking the co when he’s created no shareholder value, diluted to oblivion, stagnated revenues and can only reduce cash burn by laying people off. If they’re able to get another raise away I assume they will have laid out a clear route to programmatic and profitability as without that I can’t see IIs throwing good money after bad (again). The CEO can’t be trusted IMO it’s all jam tomorrow, little wonder he has so few shares. I bet the chairman feels aggrieved and didn’t know programmatic would be delayed.

The CEO is consistent in missing revenue guidance and diluting to oblivion. The question is will he be able to get another raise away. I suspect this will happen (if at all) this year or very early next. If there are no really encouraging and material RNSs soon I can see even more downwards pressure on the share price

They raised at 3p last year and said they would break even and programmatic launched. Didn’t happen. They raised this year at 1.25p and said programmatic would be ready in 2 months (end of June) and hoped to reach break even at some point next year. We were told end of June programmatic delayed with no timeline and we now know the major partner walked away (seems more than concerning) as they didn’t want to commit resource. Guidance down from £4m to £1.5m to £3m and cash at end of June below the year before. Cash at YE will be below the prior year. They will clearly need more cash. IIs if they are happy to put more cash in will want their pound of flesh. The thing is with demand side falling, both strategic partners, active agencies and advertisers it looks s more than risky. Why doesn’t a major snap them up for next to nothing? Something isn’t right.

This was written a long time ago so little wonder revenues are dropping and little pick up in demand side as it's hard to do and more hassle than it's worth

They have mentioned they have not secured campaigns as failed to get clearance. Seems tigerbythetail was right. no wonder they are losing revenue and clients.

From someone who works in this field... MIRI's claimed "model" simply doesn't work for sports and filmed entertainment, and can never work. LOTM simply can't / won't understand this - presumably because they don't want to recognise their losses.

At best, the "addressable market" here is tiny and niche.

I could explain at greater length about rights, not least as royalties from my previous work makes up a substantial chunk of my own income. But it would be tedious to do. But, in short, you can't just drop in adverts in post-production without paying off not only the copyright owner of the work, but all those who participated in making it. In particular, any SAG/AFTRA/Equity actors involved (and their lawyers / agents / managers) would need to approve the content of the advert (i.e. monitor for reputational damage) and be satisfied with the fee they were receiving.

In the real world it's a huge hassle for only a small payback.

Long ago I filmed some TVCs with big Hollywood stars (e.g. Bruce Willis - great guy, hope he's doing well with his illness) for Japan. You can't even begin to imagine the complexity of the negotiations with his "people".

We know Netflix and other streaming, media cos and advertising agencies were not interested in buying a distressed and vulnerable MIRI last year. We know MIRI went from 3 strategic partners to just 1 and we know demand side if falling. Is this because (as mentioned by a posted on advfn) getting permission from all the stakeholders post production very hard. Remember some stars are affiliated with brands or becomes affiliated post production so dropping a rival's branding in difficult to do, as well as other actors who want money for additional revenues, different producers affiliated with different brands, different agencies etc. Amazing MIRI only mentioned this issue recently when it was flagged a couple of years ago.

No wonder no material RNSs have been published for a long time and no wonder the major programmatic partner walked away months after signing up, they looked under the bonnet and didn;t want to commit resources to it. Also, the insertions have to be done manually (remember Amazon asked PHD students to see if they could automate it but was more than trricky). Likely a small niche market.

https://www.rte.ie/news/business/2024/1018/1476127-netflix-quarterly-results/

Sadly there is no material revenue campaign currently agreed for US advertising or it would have been subject to an RNS. I doubt we will do any campaigns for them as sign off would be a minefield. I'm hoping we can somehow get to £1.5m FY which means just £1.11m H2 and who knows we could get a grand or two from Senegal. Funny as. As well as BS I can smell something burning, oh it's cash.

Apologies, that was from Myles McNulty tweet.

The first two drugs of #AVCT's new pipeline revealed this morning. The more advanced is #AVA6103, a peptide-drug conjugate that uses the uber powerful exatecan as its warhead. Potential indications for this new PDC are: breast, lung, pancreatic and gastric cancers. Huge, intensely competitive markets.

The market leading antibody-drug conjugate, Enhertu (co-owned by Daiichi Sankyo and AstraZeneca), uses a derivative of exatecan (deruxtecan) as its warhead.

Note that the consensus forecast is for Enhertu to be generating global revenues in excess of $11bn per annum, by 2030.

Avacta clearly thinks that from the initial animal data that it has generated, AVA6103 could - at the very minimum - compete with Enhertu. More likely, it has demonstrated superior tumour-targetting ability, which one would expect(!) to result in superior efficacy.

No company has been able to harness the power of exatecan or deruxtecan without the use of a monoclonal antibody (for targetting to cell-surface antigens), in an ADC format.

To repeat, for those at the back: Avacta is now doing what no one else in the oncology world has been able to do.

It's not difficult to perceive how AVA6103 could mark a true step change in targeted oncology. And it's equally simple to understand why the likes of AstraZeneca and Daiichi - as well as all the other leading players in the ADC space - will now be on high alert.

Hugely looking forward to the unveiling of the initial pre-clinical data for AVA6103 (and #AVA7100) next week.

......

And on a "side-note", Avacta has also casually unveiled on its website that its first PDC, #AVA6000 (the pre | CSION form of doxorubicin), is now enrolling patients with triple negative breast cancer in its P1b study...! I shall repeat what I posted a couple of weeks ago:

"One of the three P1b cohorts (currently recruiting) is almost certainly to be for breast cancer. Assuming efficacy data is good, it'd be rather pointless doing a monotherapy P2 trial for that; but it would be of extremely high importance to do a P2 combo trial for 6K in replacing doxorubicin in the KEYNOTE-522 regimen (chemotherapy with Keytruda). Possible financing partners for that are somewhat obvious...!"

......

The future is very bright for Avacta.

Https://avacta.com/pipeline/

TNBC is exciting, surely a potential partner has asked to get some patients enrolled on expansion before going ahead

Preclinical results published next week at the conference and the results must be good or why bother.

Also, TNBC confirmed enrolling in 6000 which surely has to have a partner in mind if resukts are good and goes to P2 as too expensive

Https://x.com/damianreilly/status/1846660432616214859?s=46

The recent update on Avacta's website regarding the optimization of their preCISION® chemistry in what they refer to as their Gen Two PDC (Peptide Drug Conjugate) signifies several advancements in their drug development technology:

1. **Extended Half-Life**: By optimizing the conjugation process, Avacta has managed to significantly extend the half-life of the conjugated drug. The half-life of a drug determines how long it remains active in the body. An extended half-life means the drug can exert its therapeutic effects over a longer period, potentially reducing the frequency of dosing required for patients, which can improve patient compliance and quality of life.

2. **Modulation of Cleavage Rate**: The update mentions the ability to modulate the rate at which the drug (warhead) is cleaved from the conjugate (kcat/Km, which are terms from enzyme kinetics where kcat is the turnover number, and Km is the Michaelis constant). This modulation can control how quickly or slowly the active drug is released in the tumor microenvironment. Tuning this rate allows for:

- **Precision Targeting**: Ensuring that the active drug is released more specifically within or near tumor cells, thereby increasing the drug's efficacy while minimizing systemic exposure. This is crucial for reducing side effects, as the toxic warhead affects mainly the cancer cells and not the healthy tissue.

- **Pharmacokinetic Profile**: By adjusting how and when the drug is activated, Avacta can tailor the pharmacokinetics (how the drug moves through the body) to optimize therapeutic outcomes. This could mean achieving a more sustained release or a burst release, depending on what's most beneficial for treatment.

3. **Introduction of AVA6103**: Labeling AVA6103 as their first Gen Two preCISION medicine indicates it's the first candidate to benefit from these optimizations. Containing exatecan, which is described as the most potent topoisomerase I inhibitor in clinical testing, suggests:

- **High Potency**: Topoisomerase I inhibitors are important in cancer therapy as they interfere with DNA replication in cancer cells, leading to cell death. The potency of exatecan could mean lower doses might be needed, or it could be effective against cancers resistant to other treatments.

- **Targeted Therapy**: The use of exatecan in a PDC format means Avacta is attempting to harness its potency in a way that targets its delivery directly to cancer cells, leveraging the preCISION platform's tumor-specific activation to minimize collateral damage to healthy cells.

This update reflects Avacta's commitment to improving cancer treatment by enhancing the specificity, efficacy, and safety profile of chemotherapy drugs through innovative drug conjugate technology. These advancements could potentially lead to better patient outcomes with fewer side effects, marking a significant step forward in personalized ca

Jesus, just had a scan back at the joker LOTM who seems to be in another basket case HE1. Anyway, the joker is still trying to pump MIRI on other boards, this was just over a month ago. He has no shame -

I wonder if the board of director's have thought about using VPP (Virtual Product Placement) advertising to boost sales in there target markets ?

In the annual report it goes on about Senegal being a key market for them, but how are they trying to boost sales, awareness & loyalty there ?

Mirriad (MIRI & yes for the record I'm a shareholder in that company) are the content VPP specialists & have done some amazing things to help out Brands.

They have even gone so far as to have music video's created (by artists who a Brand wanted to work with), whereby they can then insert several VPP adverts seamlessly into it post production, to make it totally contextual to the viewer.

This form of advertising (VPP) gets a much better outcome for the Brand, with increased sales & Brand loyalty compared to normal adverts which the vast majority of people now try to avoid, but you can't avoid it if its in the content/video that you want to view!

Not only that but the time it takes to go ahead & run an advertising campaign can be as little as 3 weeks from initial sign-off to it being seen inside the content by viewers. It can also be done in multiple different languages as well.

I truly believe it is something that would not only help the company boost sales & awareness of the Vimto Brand etc but be much better value per ad £ spent at the same time.

*their naivety

Bentley, I have lost a fair whack through 'unicorn' PLCs listed on the AIM over the years including WAND, DVRG and have seen others lose on BIDS and many more. It's easy to get caught in the hype. I have known this co since the listed many years ago (different BOD) and invested maybe 4 years ago and have seen the same jam tomorrow in each and every presentation. I am keen to offer balance as most on here have been ramping with little substance. 2Phevs and LOTM the worst although I think coming from the right place but they're naivety rather amusing. Of the two LOTM the worst as he was actively pumping this on other boards encouraging others to buy at 2.5p when I was posting a raise was highly likely and to wait. I was derided and put on ignore and hey presto they raised at 1.25p and LOTM was on here and elsewhere apologising for his actions. He hasn't learnt a thing. LinkedIn posts mean nothing, the only thing that matters is material RNSs. Pretty much all of my predictions have come to roost, unless there is a massive uptick in revenues and material RNSs saying so the share price will start to fall before long and if the co manages to persuade more IIs to put in it will be for 0.2p or less and at least 3bn more shares. Issue is they've heard the CEO bend the truth I mean in May he was saying programmatic would be ready before end of June and then end of June it's delayed with no timeline and key partner has walked away. You can bet the IIs thought it was on schedule.

*Given the raise last year was at 3p and the one this year at 1.25p

Given the raise the year before last was at 3p and the recent one in May at 1.25p you would think IIs and the BoD would be loading up all the way down here. The last 3 TR1s are all sales. That doesn’t bode well.

Supply side can keep improving but if brands or demand side is falling by the wayside the constant drip drip has to be plugged with new clients and it doesn’t look like that’s happening. Hence they will continue to lay staff off. Not a festive season for many at mirriad. Without material RNSs and very soon this will sink further still. I can’t see them getting to Jan and issuing a trading update which will let everyone know how much cash they have as it’ll cause panic so they’ll raise beforehand. Surely this year.